Associated Genetic Biomarkers
TEK Amplification is present in 0.17% of AACR GENIE cases, with breast invasive ductal carcinoma, invasive breast carcinoma, lung adenocarcinoma, pancreatic adenocarcinoma, and anaplastic astrocytoma having the greatest prevalence .
TEK Amplification serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains TEK Amplification as an inclusion criterion, 1 is phase 2 (1 open).
Trials with TEK Amplification in the inclusion eligibility criteria most commonly target malignant solid tumor .
Cabozantinib is the most frequent therapy in trials with TEK Amplification as an inclusion criteria .
Significance of TEK Amplification in Diseases
Malignant Solid Tumor +
TEK is altered in 1.73% of malignant solid tumor patients with TEK Amplification present in 0.07% of all malignant solid tumor patients .
TEK Amplification is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TEK Amplification and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.